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counts immediate post-transplant period. Despite higher
rates in acute and chronic GVHD with FluTBI, overall out-
comes after HCT are comparable to non-TBI containing NMA
regimens for lymphoma.355
Pretransplant Immunosuppression Followed By Reduced
Toxicity Conditioning and Stem Cell Transplantation in
High Risk Thalassemia
Suradej Hongeng 1, Samart Pakakasama 2,
Usanarat Anurathapan 3, Borje S. Andersson 4. 1 Pediatrics,
Faculty of Medicine Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand; 2 Pediatrics, Ramathibodi hospital,
Bangkok, Thailand; 3 Ramathibodi hospital, Bangkok, Thailand;
4 Stem Cell Transplantation and Cellular Therapy, M. D.
Anderson Cancer Center, Houston, TX
Patients with class 3 thalassemia with high-risk features for
adverse events after high-dose chemotherapy with he-
matopoietic stem cell transplantation (HSCT) are difﬁcult to
treat, tending to either suffer serious toxicity or fail to
establish stable graft function. We performed HSCT in 21
such patients age 7 years and hepatomegaly using a novel
approach with pretransplant immunosuppression followed
by a myeloablative reduced-toxicity conditioning regimen
(ﬂudarabine and i.v. busulfan [Flu-IV Bu]) and then HSCT. The
median patient age was 15 years (range, 10 to 20 years).
Before the Flu-IV Bu + antithymocyte globulin conditioning
regimen, all patients received 1 to 2 cycles of pretransplant
immunosuppression with ﬂudarabine and dexamethasone.
Fifteen patients received a related donor graft, and 6 received
an unrelated donor graft. An initial prompt engraftment of
donor cells with full donor chimerismwas observed in all 18
patients, but 2 patients developed secondary mixed chime-
rism that necessitated withdrawal of immunosuppression to
achieve full donor chimerism. Three patients (14%) had acute
grade III-IV graft-versus-host disease, and 5 patients had
limited chronic graft-versus-host disease. The only treat-
ment-related mortality was from infection, and with a me-
dian follow-up of 50 months (range, 4 to 83), the 5-year
overall survival and thalassemia-free survival were 93%. We
conclude that this novel sequential immunoablative pre-
transplantation conditioning program is safe and effective
for patients with high-risk class 3 thalassemia exhibiting
additional comorbidities.356
Outcome Of Hematopoietic Stem Cell Transplantation For
Wiskott-Aldrich Syndrome
Sakara Hutspardol 1, Adam Gassas 2, John Doyle 3,
Muhammad Ali 2, R. Maarten Egeler 1, Eyal Grunebaum4,
Tal Schechter-Finkelstein 1. 1 Haematology/Oncology, Hospital
for Sick Children, Toronto, ON, Canada; 2Haematology/
Oncology, The Hospital for Sick Children, Toronto, ON, Canada;
3 Paediatric Hematology/Oncology, CancerCare Manitoba,
Winnipeg, MB, Canada; 4 Immunology and Allergy/ BMT
Program, Hospital for Sick Children, Toronto, ON, Canada
Wiskott-Aldrich syndrome (WAS) is an X-linked immuno-
deﬁciency presented with eczema, microthrombocytopenia,
autoimmune disorders, recurrent infections, and subsequent
malignancies. Little is known on late complications following
hematopoietic stem cell transplant (HSCT) in this population.
In a single-institutional retrospective study of 17 WAS pa-
tients who underwent HSCT between January 1992 andDecember 2012, we evaluated autoimmune manifestations,
serious infections, and graft-versus-host disease (GVHD).
Median age at HSCT was 2.17 years (range 0.28-12.38). Nine
(52.9%) and eight patients (47.1%) received bone marrow and
umbilical cord blood, respectively. Fourteen patients (82.3%)
underwent HSCT from alternative donors including unre-
lated cord, mismatch family, and match unrelated donors.
Only 2 match sibling (11.7%) and one match related (5.9%)
were used as donors. Median follow-up time was 7.05 years
(range 1.82-19.99).
Two patients (11.7%) died 1 month and 2.1 years post HSCT
due to CMV interstitial pneumonitis and severe Streptococcus
pneumoniae sepsis, respectively. Overall survival (OS) at 2-
year was 87.4%. HLA mismatch and stem cell source were not
signiﬁcant factors for OS (p¼ 0.325 and 0.886, consecutively).
In multivariate analysis, age at HSCT, HLA mismatch, and
stem cell sources were also not signiﬁcant.
Five patients (29.4%) developed acute GVHD grade II-IV. The
incidence of acute GVHD (grade II-IV) was higher when using
bone marrow as a stem cell source (p¼ 0.029). Eight (47.1%)
and three patients (17.6%) developed limited and extensive
GVHD. The incidence of chronic GVHD did not differ by age at
HSCT, HLA mismatch, and stem cell source.
Mixed donor chimerism was temporarily observed in 4 pa-
tients (23.5%). Immunosuppressant was adjusted without
donor lymphocyte infusion. Donor chimerism was subse-
quently improved.
We observed chronic GVHD-independent autoimmune
thrombocytopenia in 4 patients (23.5%). One of those four
also developed warm and cold agglutinin positive autoim-
mune hemolytic anemia. All episodes of autoimmune
thrombocytopenia occurred in patients who received cord
blood transplantation. Mixed donor chimerismwas observed
in 3 of those 4 patients who had persistent thrombocyto-
penia. Only one patient who developed autoimmune
thrombocytopenia and hemolytic anemia received treatment
of plasmapheresis and rituximab. This patient eventually
required regular intravenous immunoglobulin infusion due
to persistent hypogammaglobulinemia. Thrombocytopenia
was gradually subsided with the improvement of donor
chimerism in all patients. No malignancy occurred post-
HSCT in this retrospective cohort.
We report an excellent result using a majority of unmanip-
ulated unrelated and mismatched family donors in this
study. Cytopenias were observed in conjunction with utili-
zation of cord blood stem cells and mixed donor chimerism.357
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Introduction: Reduced intensity conditioning (RIC) allows
older patients and those with comorbidities to undergo
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effort to balance the risks of transplant-related mortality
(TRM) associated with high-dose myeloablative (MA) con-
ditioning against the risk of relapse after non-myeloablative
(NMA) conditioning in cord blood transplantation (CBT), we
investigated CBT using a novel RIC regimen of cyclophos-
phamide 50mg/kg, ﬂudarabine 150mg/m2, thiotepa 10mg/kg
and 400 cGy total body irradiation (Cy50/Flu150/Thio10/
TBI400), with favorable results (Ponce et al, BBMT 2013). We
now report outcomes of allograft using this conditioning
regimen and adult donors.
Methods: Twenty consecutive patients (median age 51 years,
range 27-69) underwent Cy50/Flu150/Thio10/TBI400 condi-
tioning for the treatment of AML (CR1 ¼ 2, CRi ¼ 2, relapse ¼
2), ALL (CR2¼1, PR¼1) CMML (CR ¼ 1, PR ¼ 1), NHL (CR1 ¼ 2,
CR2 ¼ 1, CR3 ¼ 1, refractory ¼ 5) and plasmacytoid dendritic
neoplasm (n ¼ 1). Most (n ¼ 16) had high-risk disease and a
median HCT-CI of 1 (range 0-7). All patients received
unmodiﬁed peripheral blood stem cell transplants (9 HLA-
matched related, 9 HLA-matched unrelated, and 2 HLA-
mismatched unrelated donors). Graft-versus-host disease
(GVHD) prophylaxis was with tacrolimus/methotrexate
(MTX) (n ¼ 5), ortacrolimus/sirolimus with MTX (n ¼ 12) or
without MTX (n ¼ 3). One recipient of a mismatched graft
also received anti-thymocyte globulin.
Results: All patients engrafted with a median time to
neutrophil engraftment of 12 days (range 9-19). The cumu-
lative incidence of day 100 grade II acute GVHDwas 30% (95%
CI: 12-51) with no patient having grade III-IV disease. At 2
years, 42% (95%CI: 19-64) of patients had developed chronic
GVHD of whom 2 patients had moderate and 2 had severe
disease. Two-year TRM was 23% (95%CI: 6-46) with 2 pa-
tients dying of GVHD and 2 from organ toxicity. With a
median follow-up of survivors of 19.4months (range 4.1-59.1
months), the 1 and 2-year overall survival (OS) are 74% (95%
CI: 48-88) and 59% (95%CI: 32-79), and 1 and 2-year pro-
gression-free survival (PFS) are 68% (95%CI: 43-85) and 53%
(95%CI: 27-74), respectively.
Conclusion: Adult donor allograft after Cy50/Flu150/Thio10/
TBI400 conditioning is associated with high rates of
engraftment, acceptable TRM, and promising OS and PFS in
patients with high-risk hematologic malignancies. This
regimen is an alternative to both high-dose MA and NMA
conditioning and warrants further prospective investigation.Figure 1.358
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Introduction: Allogeneic hematopoietic stem cell trans-
plantation (HSCT) utilizing myeloablative conditioning is
associated with high treatment-related mortality (TRM). In
an effort to reduce TRM yet maintain myeloablative efﬁcacy
we employed Fludarabine, intravenous Busulfan and total
body irradiation 400 cGy (Flu/Bu/TBI). We present our single
institution experience with this regimen.
Method: We conducted a retrospective analysis of 89 pa-
tients who underwent Flu/BU/TBI conditioning regimen
prior to allogeneic HSCT at our institution between the years
2007 and 2012. Flu/Bu/TBI consisted of intravenous(IV)
Fludarabine 50 mg/m2 infused over 30 minutes for 5 days
on days -6 through day -2 and IV Busulfan 3.2 mg/kg/day on
days -5 and e2 (infusion rate 80 mg/kg/hr) and TBI of
400cGY administered in divided doses on day -1 and 0. All
patients received Thymoglobulin at a dose of 4.5mg/kg or 6
mg/kg administered in divided doses on days -2, -1, and 0.
Post transplantation graft versus host disease (GVHD) pro-
phylaxis consisted of tacrolimus and mycophenolate mofe-
til. Diagnoses included Acute Myeloid Leukemia (AML)
(n¼37), Acute Lymphoblastic Leukemia (ALL) (n¼19), Mye-
lodysplastic Syndrome (MDS) (n¼10), Non-Hodgkins Lym-
phoma (NHL) (n¼12), and others (n¼11). The median age of
entire cohort was 50 years (range 21-68). CIBMTR risk
stratiﬁcation of the patients revealed high risk in the ma-
jority with only 30 (34%) patients achieving CR1 or CR2
status prior to transplant. Fourty-ﬁve (51%) patients had a
comorbidity score of 2.
Results: 1 and 3 year overall survival (OS) for the entire
cohort was 46.9% and 34.6%. OS in patients in CR when
compared to those not in CR, was signiﬁcantly better at 1 and
3 years at 73% and 55% compared to 34% and 24%( p<0.001).
OS in patients who achieved CR and had low CMS was 78% at
1 year. Cumulative incidence of progression and relapse free
survival for the entire cohort was 60.7% and 55.5% at 1 and 3
years. In patients who achieved CR, relapse free survival was
signiﬁcant at 81% and 68% at 1 and 3 years (p<0.039). Inci-
dence of grade 2 acute GVHD was 19% and grades 3-4
was12.3%. Cumulative incidence of treatment related mor-
tality (TRM) for the entire cohort at 3 years was 30.4%, but for
patients who achieved CR, the TRMwas signiﬁcantly lower at
13.3% (p<0.05)
Conclusion: Our data shows that FluBuTBI conditioning is
a well-tolerated conditioning regimen, which can provide
adequate cytoreduction while maintaining acceptable
TRM. The results are particularly encouraging for patients
who achieve remission prior to transplant and those with
low comorbidity score. In agreement with previous pub-
lications, our ﬁndings suggest that FluBuTBI is a reason-
able alternative to the traditionally used myeloablative
regimens.
